Agennix AG | Income Statement

Fiscal year is January-December. All values EUR Thousands.
2008
2009
2010
2011
Sales/Revenue
12,372.00
7,746.00
153.00
-
Cost of Goods Sold (COGS) incl. D&A
887.00
507.00
826.00
623.00
Gross Income
11,485.00
7,239.00
673.00
623.00
SG&A Expense
31,301.00
9,322.00
38,268.00
44,833.00
EBIT
19,816.00
2,083.00
38,941.00
45,456.00
Unusual Expense
1,401.00
12,763.00
108.00
260.00
Non Operating Income/Expense
4,409.00
508.00
2,753.00
2,968.00
Interest Expense
303.00
187.00
399.00
808.00
Pretax Income
21,284.00
13,079.00
36,493.00
42,626.00
Income Tax
-
1,141.00
9,491.00
800.00
Consolidated Net Income
21,284.00
11,938.00
27,002.00
41,826.00
Net Income
21,284.00
11,938.00
27,002.00
41,826.00
Net Income After Extraordinaries
21,284.00
11,938.00
27,002.00
41,826.00
Net Income Available to Common
21,284.00
11,938.00
27,002.00
41,826.00
EPS (Basic)
0.56
1.26
1.07
0.98
Basic Shares Outstanding
38,187.40
9,472.70
25,246.30
42,554.80
EPS (Diluted)
0.56
1.26
1.07
0.98
Diluted Shares Outstanding
38,187.40
9,472.70
25,246.30
42,554.80
EBITDA
18,929.00
1,576.00
38,115.00
44,833.00
Non-Operating Interest Income
1,843.00
1,446.00
202.00
410.00

About Agennix

View Profile
Address
Im Neuenheimer Feld 515
Heidelberg Baden Wuerttemberg 69120
Germany
Employees -
Website http://www.agennix.com
Updated 09/14/2018
Agennix AG is a biopharmaceutical company, which engages in the development of protein-based drugs for oncology, asthma and wound healing. Its clinical development programs include oral talactoferrin alfa and RGB-286638. The company was founded on November 5, 2009 and is headquartered in Heidelberg, Germany.